CORPORATE MILESTONES

Year Descriptions
2015
Construction for C&O’s new production base was completed and put into use.

2014
C&O launched the first “Injection of Rabeprazole Sodium - Aobo Ping ®” in China, which is the independently developed product.

2011
Shionogi became the controlling shareholder with shareholding of 71% held in C&O.

2011
C&O was appointed as the exclusive distributor of Flumarin® in China by Shionogi.
2010
Sumitomo became the strategic shareholder with shareholding of 29% held in C&O.

2008
Acquired 100% shareholding in Nanjing Xinaokang

2008
Established the joint venture with XenoBiotic Laboratories, Inc.

2007
C&O was appointed as the distributor of the new generation cephalosporin antibiotics, ”Meiact” for the whole of China by Shantou Meiji Pharmaceuticals Co., Ltd.

2007
C&O was appointed as the exclusive distributor of “Europharm cough syrup for children - Pholcotussin” in China by Europharm Laboratories Co., Ltd.

2006
Acquired 100% shareholding in Shenzhen Liancheng

2006
Acquired 69.98% shareholding in Shanghai Sun-sail

2001
Acquired 100% shareholding in Nanjing Chang Ao

2001
Nanjing Chang Ao established the research and development center to conduct the relevant activities for C&O.

2001
Nanjing Chang Ao obtained the GMP certification by the SFDA.

2001
C&O obtained the exclusive distributorship rights on 4 products in China from Bright Future Pharmaceutical Laboratories Limited.

2000
Expanded the Freeze-dried Powder Workshop, Ointment and Cream Workshops

1999
Expanded the Tablets and Capsules Workshop, and Raw Materials Workshop

1997
Nanjing Chang Ao was established and engaged in the manufacture and sales of own branded products.

1995
C&O was established and engaged in the manufacture and sales of own branded products and distribution of third parties’ products



Page Updated as at 04/06/18